FLFeng Long

Feng Long

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Feng Long has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Sun

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, Huashan Hospital, National Medical Center for Infectious Diseases, Fudan University, Shanghai, China

    1 shared publication
  • Haihua Yang

    Department of Respiratory Medicine, Huashan Hospital North, Fudan University Shanghai 201907, China

    1 shared publication
  • Haoxiang Zhu

    Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Huajian Ying

    Department of Nephrology, Huashan Hospital Fudan University, Shanghai, China

    1 shared publication
  • Jie Yu

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, Huashan Hospital, National Medical Center for Infectious Diseases, Fudan University, Shanghai, China

    1 shared publication
  • Jiming Zhang

    Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Department of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University

    1 shared publication

Latest Publications

  • Open Access

    In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study

    by Yue Guo, Yifei Guo, Huajian Ying, Weien Yu, Shiqi Chen, Yao Zhang, Shenyan Zhang, Yanxue Lin, Feng Sun, Yongmei Zhang, et al.

    Introduction: The SARS-CoV-2 Omicron variant has decreased virulence and pathogenicity, yet the number of Omicron infections worldwide is unprecedentedly high, with rather high mortality and severe disease rate. Chronic kidney disease (CKD) patients are particularly vulnerable to the SARS-CoV-2 Omicron variant and have unique clinical outcomes. Methods: We retrospectively collected data from 2140 hospitalized patients with SARS-CoV-2 Omicron variant infection from March 29, 2022, to May 17, 2022. Demographic characteristics, ancillary examination results, and clinical treatments were described. Occurrence of critical COVID-19 or death and time of positive-to-negative conversion was defined as primary outcomes. The presence of COVID-19 pneumonia and the usage of respiratory or circulatory support was defined as secondary outcomes. Univariate or multivariate logistic regression analyses were performed to identify risk factors for primary outcomes. Results: 15.74% of CKD patients infected with the SARS-CoV-2 Omicron variant ended up with critical COVID-19 or death. Pre-existing CKD was a risk factor for critical COVID-19 or death and prolonged time of positive-to-negative conversion of SARS-CoV-2. Nirmatrelvir-ritonavir facilitated viral clearance among COVID-19 patients with non-severe CKD. Conclusion: We found patients with CKD and COVID-19 due to Omicron experienced worse clinical outcomes and prolonged time of positive-to-negative conversion of SARS-CoV-2 compared to patients without CKD, which helps rationalize limited medical resources and offers guidance for appropriate clinical treatments.


    • 15 October 2015
      • Vol. 8  (10) , 17941-9

    Association between EPHX1 rs1051740 and lung cancer susceptibility: a meta-analysis.

    by Peng Zhang, Youzhi Zhang, Haihua Yang, Wenjing Li, Xiaodong Chen, Feng Long

    Microsomal epoxide hydrolase 1 (EPHX1) may play an important role in epigenetic change and DNA repair concerned with lung cancer. Several studies have investigated the association between EPHX1 rs1051740 and lung cancer risk, but there is no consensus. Therefore, we performed a meta-analysis to further identify the relationship. The Pubmed and Embase databases were searched for eligible studies. An odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the correlation between EPHX1 rs1051740 polymorphism and lung cancer risk through a meta-analysis. Overall, no significant relationship was found between EPHX1 rs1051740 and lung cancer risk (CC vs. TT: OR=1.10, 95% CI=0.88-1.36; CC+CT vs. TT: OR=1.02, 95% CI=0.88-1.18; CC vs. TT+CT: OR=1.08, 95% CI=0.91-1.27; C vs. T: OR=1.04, 95% CI=0.93-1.17; CT vs. TT: OR=0.98, 95% CI=0.85-1.13). Nevertheless, further subgroup analysis by ethnicity demonstrated that EPHX1 rs1051740 with CC genotype or C allele was an increased risk for lung cancer in Asians (CC vs. TT: OR=1.54, 95% CI=1.23-1.94; CC vs. TT+CT: OR=1.43, 95% CI=1.20-1.71; C vs. T: OR=1.26, 95% CI=1.08-1.47). This meta-analysis indicates that EPHX1 rs1051740 with CC genotype or C allele may be a risk factor in Asians.